spacer
home > ict > summer 2019 > choosing a winning model
PUBLICATIONS
International Clinical Trials

Choosing a Winning Model





How you approach implementing functional service provision (FSP) within your company has a direct effect on how successful those FSP teams will be. A ‘sustainable quality’ approach starts with picking the right model and navigating several areas of focus to ensure its success: planning, training, cultural fit, staff retention, technology, communication, agility, sponsor participation, performance indicators, expectations management, etc.

There are four basic models: uncapped time and materials (T&M), capped T&M, fixed fee, and ring-fenced/ full-time equivalents (FTEs) − each with pros and cons based on trial requirements and real-world experience.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Jo Marshall is the Director of FSP and UK Country Manager for CROS NT. Jo entered the industry as a clinical data manager for Searle and held global data management roles for Pharmacia and Pfizer before moving to a specialist biometrics consultancy and contributing to the growth of that company first as Associate Director, then Managing Director until its sale to CROS NT in 2013. Since being at CROS, she has supported a variety of initiatives including commercial, quality, efficiency, and product development, as well as operational department management for the statistical programming team. She holds an MSc in Clinical Data Management, is the treasurer for the Association for Clinical Data Management (ACDM), and chaired the ACDM conference organising committee for a number of years.


Print this page
Send to a friend
Privacy statement
News and Press Releases

IMFINZITM (durvalumab) WITH CHEMOTHERAPY DEMONSTRATED A SUSTAINED OVERALL SURVIVAL BENEFIT IN 1ST-LINE EXTENSIVE-STAGE SMALL CELL LUNG CANCER IN THE PHASE III CASPIAN TRIAL

Detailed results from an updated analysis of the Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.
More info >>

White Papers

CRSF Label - Child-Resistant Blister Packs With Booklet Label

Faubel & Co. Nachfolger GmbH

This case study explains how Faubel was commissioned by a leading global pharmaceutical company to develop a label for an aluminum blister pack with 14 cavities, which was used as part of a multinational clinical trial. This label was intended to both protect infants from erroneous ingestion and facilitate use by seniors.
More info >>

 
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement